Astrazeneca (AZN) Total Non-Current Liabilities (2009 - 2026)

Astrazeneca (AZN) has reported Total Non-Current Liabilities for 18 consecutive years, with -$34.1 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 5.37% year-over-year to -$34.1 billion; the TTM figure through Mar 2026 stood at -$34.1 billion (up 5.37% YoY), while the FY2025 annual figure was -$34.7 billion, down 198.41% from the prior year.
• Total Non-Current Liabilities came in at -$34.1 billion for Q1 2026 at Astrazeneca, up from -$34.7 billion in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $35.3 billion in Q4 2024, with the low at -$41.2 billion in Q1 2022.
• Average Total Non-Current Liabilities over 5 years is -$23.3 billion, with a median of -$34.4 billion recorded in 2025.
• Across the five-year window, Total Non-Current Liabilities advanced 21.71% in 2022 and sank 198.41% in 2025, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $33.1 billion in 2022, then dropped by 5.19% to $31.4 billion in 2023, then rose by 12.37% to $35.3 billion in 2024, then tumbled by 198.41% to -$34.7 billion in 2025, then gained by 1.95% to -$34.1 billion in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered -$34.1 billion, -$34.7 billion, and -$34.4 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.